Tetricus Labs, a New Haven-based precision psychiatry company that is developing a digital platform to evaluate and monitor patients in mental health treatment, has been accepted to the One Mind Accelerator, a national program which backs early-stage startups.
Philip Corlett, PhD, associate professor of psychiatry, is scientific co-founder of Tetricus.
Tetricus is one of 10 companies selected for the business development program. Each company will be given $100,000 and will engage in 10 weeks of intensive programming designed to rapidly grow their business.
One Mind is a leading mental health non-profit that heals lives through brain research. It will leverage its vast network of world-class investors, founders, operators, scientists, payers, providers, policymakers, and lived experience advocates to promote each company in the Accelerator program.
“Our nation is facing a mental health crisis. Serious mental illness, which impacts more than 14 million people in the U.S. at a cost of $318 billion annually, is still desperately undeserved,” said Brandon Staglin, president of One Mind and a schizophrenia survivor. “The One Mind Accelerator will serve as a force-multiplier for entrepreneurs tackling some of the hardest problems in mental health so that people who are suffering the most get access to the treatments and services they need, with the sense of urgency they deserve.”
The Accelerator will provide 10 weeks of programming that covers all aspects of building a mental health company, from working with payers and providers, to pursuing regulatory approval, to designing category-defining companies that adhere to the highest ethical standards. Co-creating with the lived experience community will be an important aspect of the program, helping founders to build products that accurately address the needs of their target market.
Tetricus’ first product, Sigmund.AI, is a machine learning-based patient evaluation that uses novel tools to assess diagnosis and acuity for patient triage and remote monitoring in hospital and clinical trial contexts.